Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Boston Scientific Corporation (BSX) is a leading medical devices business based in the US. It opened the day at USD$40.38 after a previous close of USD$40.43. During the day the price has varied from a low of USD$40.125 to a high of USD$41.48. The latest price was USD$40.86 (25 minute delay). Boston Scientific is listed on the NYSE and employs 41,000 staff. All prices are listed in US Dollars.
| Open | $40.38 |
|---|---|
| High | $41.48 |
| Low | $40.13 |
| Close | $40.86 |
| Previous close | $40.43 |
| Change | $0.43 |
| Change % | 1.0636% |
| Volume | 9,850,850 |
| 52-week range | $37.96 - $47.50 |
|---|---|
| 50-day moving average | $42.86 |
| 200-day moving average | $43.00 |
| Wall St. target price | $50.38 |
| PE ratio | 74 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.53 |
Historical closes compared with the close of $40.86 from 2022-05-25
| 1 week (2022-05-18) | 1.57% |
|---|---|
| 1 month (2022-04-22) | N/A |
| 3 months (2022-02-23) | -6.52% |
| 6 months (2021-11-26) | 5.94% |
| 1 year (2021-05-26) | -2.32% |
|---|---|
| 2 years (2020-05-26) | 12.90% |
| 3 years (2019-05-24) | 6.21% |
| 5 years (2017-05-26) | 49.56% |
Valuing Boston Scientific stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Boston Scientific's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 74x. In other words, Boston Scientific shares trade at around 74x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Boston Scientific's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3897. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Boston Scientific's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.2 billion.
The EBITDA is a measure of a Boston Scientific's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $12.2 billion |
|---|---|
| Operating margin TTM | 17.47% |
| Gross profit TTM | $8.2 billion |
| Return on assets TTM | 4.2% |
| Return on equity TTM | 4.99% |
| Profit margin | 6.66% |
| Book value | $11.71 |
| Market capitalisation | $56.1 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Social score: 12.87/100
Governance score: 7.87/100
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific hasn't always managed to keep its nose clean.
We're not expecting Boston Scientific to pay a dividend over the next 12 months.
Boston Scientific's shares were split on a 2:1 basis on 5 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific shares which in turn could have impacted Boston Scientific's share price.
Over the last 12 months, Boston Scientific's shares have ranged in value from as little as $37.96 up to $47.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific's is 0.8147. This would suggest that Boston Scientific's shares are less volatile than average (for this exchange).
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Your detailed review of share trading with BlackBull Markets, including brokerage fees, safety, pros and cons, and more.
Thinking of trading shares with Jarden Direct? Check out our review of Jarden Direct fees, safety, and pros and cons first.
Your detailed review of online share trading with Tiger Brokers, including fees, markets, safety, pros and cons, and how to sign up.
A growing number of Kiwis are investing in the stock market via an app or online platform, according to research by Finder.
The second Bitcoin future ETF is set to go live Oct. 22. Here’s how to invest if you’re in New Zealand.
Steps to owning and managing VanEck Bitcoin Strategy ETF units.
Steps to owning and managing ProShares Bitcoin Strategy ETF, with 24-hour and historical pricing before you buy.
We present the 10 best performing shares on the NZX over the last 3 months and show you how you can invest in them.
Fractional shares are fractions of company shares. Sometimes they’re made by brokers to allow those with limited funds to get access to stocks.
How day trading works, what to watch out for and how to pick a broker.